Bioorganic and Medicinal Chemistry Letters
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Synthesis of non-nucleoside anti-viral cyclopropylcarboxacyl hydrazones and initial anti-HSV-1 structure-activity relationship studies.
30:127559-127559.
2020
-
Synthesis of α-methylstilbenes using an aqueous Wittig methodology and application toward the development of potent human aromatase inhibitors.
29:1395-1398.
2019
-
Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging.
29:986-990.
2019
-
One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii.
28:1642-1646.
2018
-
Discovery of potent antiviral (HSV-1) quinazolinones and initial structure-activity relationship studies.
27:4601-4605.
2017
-
Design and synthesis of [ 125 I]Pyricoxib: A novel 125 I-labeled cyclooxygenase-2 (COX-2) inhibitors.
26:1516-1520.
2016
-
Evaluation of synthetic coumarins for antiausterity cytotoxicity against pancreatic cancers.
26:1471-1474.
2016
-
Tris(3-hydroxypropyl)phosphine (THPP): A mild, air-stable reagent for the rapid, reductive cleavage of small-molecule disulfides.
25:4114-4117.
2015
-
Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.
25:2133-2140.
2015
-
Antimitotic activity of structurally simplified biaryl analogs of the anticancer agents colchicine and combretastatin A4.
25:117-121.
2015
-
Inhibition of the ANT(2″)-Ia resistance enzyme and rescue of aminoglycoside antibiotic activity by synthetic α-hydroxytropolones.
24:4943-4947.
2014
-
Discovery of a new class of cinnamyl-triazole as potent and selective inhibitors of aromatase (cytochrome P450 19A1).
24:4586-4589.
2014
-
Discovery of 1-arylpyrrolidone derivatives as potent p53–MDM2 inhibitors based on molecule fusing strategy.
24:2648-2650.
2014
-
Development of tag-free photoprobes for studies aimed at identifying the target of novel Group A Streptococcus antivirulence agents.
24:1538-1544.
2014
-
Designing analogs of ticlopidine, a wall teichoic acid inhibitor, to avoid formation of its oxidative metabolites.
24:905-910.
2014
-
Investigation of aryl halides as ketone bioisosteres: Refinement of potent and selective inhibitors of human cytochrome P450 19A1 (aromatase).
23:6060-6063.
2013
-
Chemical variation from the neoantimycin depsipeptide assembly line.
23:5123-5127.
2013
-
Erratum to “Degradation of MAC13243 and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone LolA” [Bioorg. Med. Chem. Lett. 23 (2013) 2426–2431].
23:4469-4470.
2013
-
Structures and biosynthesis of 12-membered macrocyclic depsipeptides from Streptomyces sp. ML55.
23:4150-4153.
2013
-
Degradation of MAC13243 and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone LolA.
23:2426-2431.
2013
-
N-demethylation of cyamemazine via non-classical Polonovski reaction and its conjugation to bovine serum albumin.
22:2160-2162.
2012
-
Discovery of a novel class of aldol-derived 1,2,3-triazoles: Potent and selective inhibitors of human cytochrome P450 19A1 (aromatase).
22:718-722.
2012
-
Structure–activity studies on acetylcholinesterase inhibition in the lycorine series of Amaryllidaceae alkaloids.
20:5290-5294.
2010
-
Potent and selective inhibition of human cytochrome P450 3A4 by seco-pancratistatin structural analogs.
20:2335-2339.
2010
-
Structure–activity studies on seco-pancratistatin analogs: Potent inhibitors of human cytochrome P450 3A4.
19:5607-5612.
2009
-
Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids.
19:3233-3237.
2009
-
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.
19:1026-1029.
2009
-
Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
17:4491-4494.
2007
-
A synthesis of 3-deoxydihydrolycoricidine: Refinement of a structurally minimum pancratistatin pharmacophore.
15:5315-5318.
2005
-
Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
14:5465-5467.
2004
-
High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate.
13:2493-2496.
2003
-
Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers.
11:51-54.
2001
-
Studies directed towards the refinement of the pancratistatin cytotoxic pharmacophore.
11:169-172.
2001
-
Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of l-prolyl-l-leucyl-glycinamide (PLG).
9:2349-2352.
1999
-
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor.
9:1773-1778.
1999
-
Synthesis and evaluation of photoaffinity probes directed at lanosterol 14α-demethylase (P-45014DM).
2:383-386.
1992
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)